Application of compound SAICAR in preparation of product for promoting wound healing
The compound SAICAR promotes the expression and re-epithelialization of wound COL17, which solves the problem that existing wound treatment technology has failed to effectively target the pathological mechanism at the microscopic level, and has achieved efficient repair of acute and difficult wounds, with clear therapeutic targets and relative High efficiency and high safety, and reduce costs.
Patent Information
- Application Number
- CN202411221006.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-02
- Publication Date
- 2024-12-06
AI Technical Summary
The existing wound treatment technologies mainly focus on macro-level healing, and fail to effectively target the pathophysiological mechanism at the micro-level, resulting in unknown therapeutic targets, limited efficacy, and high safety and preparation costs of skin transplantation and other technologies.
The compound SAICAR (C13H19N4O12P) is used as a drug to promote wound COL17 expression and re-epithelialization, thereby promoting wound healing. Pharmaceutical acceptable carriers are used, dosage forms include injections, emulsions, etc. The SAICAR concentration is 1-100μM, especially for acute and Repair of difficult wounds.
It has achieved accurate and effective repair of acute and difficult wounds, with clear therapeutic targets, high efficiency and high safety compared to traditional methods, and has reduced preparation costs.
Smart Images

Figure CN119074740A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of wound treatment, and in particular to use of the compound SAICAR in preparing a product for promoting wound healing. Background Art
[0002] Trauma is the disease with the highest incidence and the highest rate of deformity and disability worldwide, accounting for 12% of all diseases. Among the injuries caused by trauma, skin defects are the most common, with more than 10 million new cases each year. When the skin defect is too large, the wound is seriously infected, or the patient's basic conditions are poor, the wound often does not heal, which has a significant impact on the patient's quality of life and the national medical burden. Existing wound treatment technologies that can promote wound healing include: (1) moist dressings; (2) growth factors, cytokines, etc.; (3) bioengineering materials; (4) skin transplants, epidermal substitutes, and stem cells, etc.
[0003] In order to promote the repair of various acute and difficult-to-heal wounds, scholars have conducted many in-depth explorations. Currently, commonly used moist dressings, growth factors, cytokines, bioengineering materials and other products are mainly focused on macro-level healing, but not on micro-level pathophysiological mechanisms. Therefore, the treatment targets are unclear and the efficacy is limited; the safety and preparation costs of technologies such as skin transplantation, epidermal substitutes and stem cells have become the biggest limitations of their clinical application. Therefore, although a large number of products that promote wound healing have been developed at the preclinical or clinical level in recent years, no matter what method is used, the repair of acute and difficult-to-heal wounds is still a bottleneck that has not yet been overcome.
[0004] The latest research suggests that collagen type 17 (COL17) plays an important role in the healing process of skin wounds. Reduced expression of COL17 will hinder the wound healing process and delay wound healing. Therefore, if effective drugs can be found to target and upregulate COL17 expression, it will be possible to provide a new, accurate and effective clinical treatment method for promoting skin wound healing. Summary of the invention
[0005] In order to solve the above problems, the present invention provides the use of the compound SAICAR in preparing a product for promoting wound healing, wherein the SAICAR (C 13 H 19 N4O 12 The general chemical structure of P) is as follows:
[0006]
[0007] Furthermore, the SAICAR promotes wound healing by promoting COL17 expression and re-epithelialization on the wound surface.
[0008] Furthermore, the wound surface includes common wound surface and diabetic wound surface.
[0009] Further, the product comprises SAICAR and a pharmaceutically acceptable carrier. "Pharmaceutically acceptable" means that when the carrier is properly administered to an animal or a human, they do not produce adverse, allergic or other adverse reactions. The pharmaceutically acceptable carrier can be selected from one or more of a diluent, a filler, a surfactant, an absorption promoter, a disintegrant, a wetting agent, a dispersant, and the like.
[0010] Furthermore, the concentration of SAICAR in the product is 1-100 μM.
[0011] Furthermore, the concentration of SAICAR in the product is 5-50 μM.
[0012] Furthermore, the dosage form of the product includes but is not limited to any one of injection, emulsion, tablet, powder, granule, gel, ointment, liposome, and oral solution.
[0013] The present invention also provides a pharmaceutical composition for promoting wound healing, which contains SAICAR as an effective ingredient.
[0014] Furthermore, the pharmaceutical composition comprises SAICAR and a pharmaceutically acceptable carrier.
[0015] Furthermore, the concentration of SAICAR in the pharmaceutical composition is 1-100 μM.
[0016] The present invention has the following beneficial effects:
[0017] 1. The present invention promotes the expression of COL17 in wounds by using SAICAR, thereby promoting the repair of acute and refractory wounds, and provides a new accurate and effective clinical treatment method for promoting the healing of skin wounds.
[0018] 2. The present invention proposes for the first time the use of SAICAR as a drug for promoting wound healing; compared with moist dressings, growth factors, cytokines, bioengineering materials, etc., the drug involved in the present invention has a clear therapeutic target and higher efficiency; compared with skin transplantation, epidermal substitutes and stem cells and other technologies, it has higher safety.
[0019] 3. The drug product involved in the present invention has significant cost advantages over currently available drugs and has a lower synthesis cost. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 : Western blot experimental results of human epidermal keratinocytes in Example 1.
[0021] Figure 2: Results of the cell scratch test in Example 1. In the figure, the left is a photo of scratched cells treated with SAICAR solutions of different concentrations, and the right is a photo of the cell wound healing rate after being treated with SAICAR solutions of different concentrations.
[0022] Figure 3 : Results of the EdU cell proliferation experiment in Example 1. In the figure, the left side shows the color development of EdU-stained cells after being treated with SAICAR solutions of different concentrations, and the right side shows the proportion of EdU-stained positive cells after being treated with SAICAR solutions of different concentrations.
[0023] Figure 4 : Western blot results of the refractory wound tissues of diabetic mice in Example 2. In the figure, the left is the Western blot experimental development diagram, and the right is the quantitative analysis results of COL17 and phosphorylated STAT3.
[0024] Figure 5 : The results of histological HE staining of the refractory wounds of diabetic mice in Example 2. In the figure, the left is the HE staining photo of the tissue, and the right is the re-epithelialization rate.
[0025] Figure 6 : The healing of refractory wounds in diabetic mice in Example 2. In the figure, the left side shows the general view of the changes in wound healing area, and the right side shows the wound healing rate at different times.
[0026] Figure 7 : The wound healing of normal mice in Example 2. In the figure, the left side shows the general view of the change of wound healing area, and the right side shows the wound healing rate at different times. DETAILED DESCRIPTION
[0027] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments.
[0028] Example 1: In vitro experiments
[0029] 1. Experimental Materials
[0030] 1.1 The SAICAR solution is prepared as follows:
[0031] SAICAR was purchased from MCE (Cat. No. HY-126585) and dissolved in sterile water to prepare a 10 mM stock solution. In in vitro experiments, it was added to the culture medium to prepare a 5 or 10 μM solution.
[0032] 2. Experimental Methods
[0033] 2.1 SAICAR treatment, cell protein extraction and Western blot
[0034] Human epidermal keratinocytes (HaCaT cells) were seeded in six-well plates. When the cell density reached 50%, the cells were starved overnight and then treated with 10 μM SAICAR solution (diluted with complete culture medium) for 24 hours. Proteins were extracted, 4× protein SDS-PAGE loading buffer was added, and heated at 95°C. Electrophoresis was performed using a 10% SDS-PAGE gel to separate proteins. The membrane was transferred using a PVDF membrane. After transfer, the membrane was blocked with 5% skim milk for 1 hour. Primary antibodies were added and incubated overnight at 4°C. The peroxidase-conjugated secondary antibody was added the next day and incubated at room temperature for 1 hour. After adding the developer, the chemiluminescence imaging system was used for development.
[0035] 2.2 SAICAR treatment and cell scratch assay
[0036] Human epidermal keratinocytes (HaCaT cells) were passaged into 6-well plates at a confluence rate of 80-90%, and the scratch experiment was started when the cell monolayer was fused. Scratch the wells with a 200 μL yellow gun tip, rinse and take pictures with an inverted microscope. SAICAR solutions (diluted with serum-free medium) at concentrations of 0, 5, and 10 μM were added to the cells. Cell photos at the same position were taken after 96 hours of culture. The scratch area was measured using ImageJ software, and the cell wound healing rate = (measured area at the detection time point - measured area at scratch 0h) / measured area at scratch 0h.
[0037] 2.3 EdU cell proliferation assay
[0038] Human epidermal keratinocytes (HaCaT cells) were cultured at 1.5×10 4 The cells were inoculated into 96-well plates, and the experiment was started after the cells were completely attached. SAICAR solution (diluted with complete culture medium) with concentrations of 0, 5, and 10 μM was added to the cells and cultured for 24 hours. EdU working solution was incubated for 1.5 hours. The cells were fixed and permeabilized. After staining with Click reaction solution and Hoechst33342, the cells were photographed under an inverted microscope. Image J software was used to count the number of cells showing blue and green fluorescence in each field of view, and the proportion of EdU-positive cells was calculated.
[0039] 3. Experimental results
[0040] 3.1 SAICAR promotes STAT3 phosphorylation in human epidermal keratinocytes and upregulates COL17 expression
[0041] First, the effect of SAICAR on human epidermal keratinocytes was studied in vitro. It was found that after treatment with 10 μM SAICAR, the phosphorylation level of STAT3 in human keratinocytes (HaCaT cells) increased, and the expression level of COL17 increased significantly ( Figure 1 ).
[0042] 3.2 SAICAR promotes migration of human epidermal keratinocytes
[0043] Human epidermal keratinocytes (HaCaT cells) were treated with SAICAR and a scratch test was performed. The results showed that 5 and 10 μM SAICAR significantly promoted the migration ability of HaCaT cells (P<0.01) ( Figure 2 ).
[0044] 3.3 SAICAR can promote the proliferation of human epidermal keratinocytes
[0045] Human epidermal keratinocytes (HaCaT cells) were treated with SAICAR and EdU cell proliferation assay was performed. The results showed that 10 μM SAICAR significantly promoted the migration ability of HaCaT cells (P<0.01) ( Figure 3 ).
[0046] Example 2: In vivo experiments
[0047] 1. Experimental Materials
[0048] 1.1 The SAICAR solution is prepared as follows:
[0049] SAICAR was purchased from MCE (Cat. No. HY-126585) and dissolved in sterile water to prepare a 10 mM stock solution. In the in vivo experiment, physiological saline was added to prepare a 50 μM solution.
[0050] 2. Experimental Methods
[0051] 2.1 Establishment of mouse wound healing model and SAICAR injection
[0052] First, a wound healing model was established. 8-week-old C57 / BL6 (normal mice) and BKS-db / db mice (diabetic mice) were anesthetized and the back skin was prepared; a full-thickness skin excision wound with a diameter of 8 mm was made at the symmetrical positions on both sides of the midline of the back and the carnosus was subtracted. After the model was established, it was divided into: control group (solvent control) and SAICAR treatment group (50 μM), and 100 μL of the corresponding reagent was injected subcutaneously at the wound edge every other day. For normal mice, the mice were photographed and recorded immediately after surgery, on the 3rd, 5th, 7th, and 10th days. For diabetic mice, the mice were photographed and recorded immediately after surgery, on the 5th, 7th, 9th, and 12th days, and the wound area was counted using ImageJ. Another batch of diabetic mice was euthanized on the 7th day after surgery and the 1mm wound edge skin around the wound was collected for quick freezing or soaking in 4% paraformaldehyde for subsequent experiments.
[0053] 2.2 Tissue sections and HE staining
[0054] Fresh tissues were fixed in 10% formalin solution for more than 24 hours, then embedded in paraffin and cut into 4 μm sections. The sections were dewaxed and hydrated, then stained with hematoxylin solution (Harris) and eosin solution, and observed under an upright microscope.
[0055] 2.3 Western blot
[0056] Add RIPA lysis buffer (containing 1% PMSF) to the tissue and lyse on ice for 30 minutes. Centrifuge to obtain the supernatant, add 4× protein SDS-PAGE loading buffer, and heat at 95°C. Use 10% SDS-PAGE gel for electrophoresis to separate proteins. Transfer to PVDF membrane. After transfer, block with 5% skim milk for 1 hour. Add primary antibody and incubate overnight at 4°C. Add peroxidase-conjugated secondary antibody the next day and incubate at room temperature for 1 hour. Add developer and use chemiluminescence imaging system for development. Use Image J software for quantitative analysis of bands.
[0057] 3. Experimental results
[0058] 3.1 SAICAR promotes STAT3 phosphorylation and COL17 expression in refractory wound tissues of diabetic mice
[0059] A classic mouse wound healing model was established in diabetic mice to simulate the healing process of difficult-to-heal wounds in human diabetes. Samples were obtained on the 5th day after wound establishment, and tissue proteins were extracted for WB detection. The results showed that the expression of phosphorylated STAT3 and COL17 in the SAICAR treatment group was significantly increased, with statistical significance (COL17, P<0.001; phosphorylated STAT3, P<0.05) ( Figure 4 ).
[0060] 3.2 SAICAR promotes re-epithelialization of refractory diabetic wounds
[0061] Samples were obtained for HE staining on the 7th day after the wound healing model was established. The results showed that after injection of 50μM SAICAR, the re-epithelialization rate of the mouse wound epidermis was significantly increased (P < 0.001) ( Figure 5 ).
[0062] 3.3 SAICAR promotes healing of refractory diabetic wounds
[0063] After the wound healing model was established, the wound healing conditions of diabetic mice in different groups were recorded by taking photos on the 5th, 7th, 9th and 12th days. The results showed that after injection of 50μM SAICAR, the wound area of mice at each time point was significantly reduced compared with the control group (P<0.05)( Figure 6 ).
[0064] 3.4 SAICAR promotes wound healing in normal mice
[0065] After the wound healing model was established, the wound healing conditions of the normal mice in different groups were recorded by taking photos on the 3rd, 5th, 7th and 10th days. The results showed that after injection of 50μM SAICAR, the wound area of the mice at each time point was significantly reduced compared with the control group (P<0.01)( Figure 7 ).
[0066] This specific implementation is only an explanation of the present invention, not a limitation of the present invention. Any changes made by those skilled in the art after reading the specification of the present invention will be protected by the patent law as long as they are within the scope of the claims of the present invention.
Claims
1. Use of the compound SAICAR in the preparation of products for promoting wound healing.
2. Use of the compound SAICAR according to claim 1 in preparing a product for promoting wound healing, characterized in that: The SAICAR promotes wound healing by promoting COL17 expression and re-epithelialization on the wound surface.
3. Use of the compound SAICAR according to claim 1 in preparing a product for promoting wound healing, characterized in that: The wound surface includes common wound surface and diabetic wound surface.
4. Use of the compound SAICAR according to claim 1 in preparing a product for promoting wound healing, characterized in that: The product comprises SAICAR and a pharmaceutically acceptable carrier.
5. Use of the compound SAICAR according to claim 4 in the preparation of a product for promoting wound healing, characterized in that: The concentration of SAICAR in the product is 1-100 μM.
6. Use of the compound SAICAR according to claim 5 in preparing a product for promoting wound healing, characterized in that: The concentration of SAICAR in the product is 5-50 μM.
7. Use of the compound SAICAR according to claim 4 in the preparation of a product for promoting wound healing, characterized in that: The pharmaceutically acceptable carrier is selected from one or more of a diluent, a filler, a surfactant, an absorption enhancer, a disintegrant, a wetting agent, and a dispersant.
8. Use of the compound SAICAR according to claim 4 in the preparation of a product for promoting wound healing, characterized in that: The dosage form of the product is injection, emulsion, tablet, powder, granule, gel, ointment, liposome or oral solution.
9. A pharmaceutical composition for promoting wound healing, characterized in that: Contains SAICAR as the active ingredient.
10. The pharmaceutical composition for promoting wound healing according to claim 9, characterized in that: It comprises SAICAR and a pharmaceutically acceptable carrier.
